Skip to main content
. Author manuscript; available in PMC: 2014 Mar 20.
Published in final edited form as: Pharmacogenomics. 2012 Jun;13(8):901–915. doi: 10.2217/pgs.12.72

Table 1. Properties of currently available next-generation sequencing technologies.

Platform Read length Throughput/
run
Approximate
time/run
Machine
cost (US$)
Reagent
cost (US$)
Reagent
cost/Gb
(US$)
Primary
error
Base error rates
HiSeq™ 2000 100 bp 600 Gb 11 days 690,000 23,470 40 Substitution ~1–2% over 100 bp
SOLiD™ 4 75 bp 100 Gb 12 days 475,000 8128 <110 A–T bias 0.06%
SOLiD™ 4hq 75 bp 300 Gb 14 days 595,000 10,503 70 A–T bias 0.01%
SOLiD™ PI 75 bp 77 Gb 8 days 349,000 6101 80 A–T bias 0.01%
454GSFLX Titanium XL+ 700 mean bp, ≤1000 bp 700 Mb 23 h 500,000 6200 7000 Indel 0.5%
lonTorrent™ PGM™ 316 200 bp 100 Mb ~2 h 50,000 750 <7500 Indel 1.2% over 150 bp
lonTorrent™ PGM™ 318 200 bp 1 Gb ~2 h 50,000 925 <925 Indel 1.2% over 150 bp
MiSeq® 150 bp >1 Gb 27 h 125,000 750 740 Substitution ~1–2% over 100 bp
454 GS Junior 400 mean bp 35 Mb 12 h 108,000 1100 22,000 Indel 1.00%
PacBioRS (early 2012) 2700 mean bp, ≤5000 bp 90 Mb per cell <1 day (?) 695,000 110–1700 11,000-
340,000
CG deletion 13.00%

Currently available next-generation sequencing technologies. All specifications are liable to rapid change. Cost information is taken from Glenn [18], but can vary widely by country and individual deal. The read lengths given are taken from manufacturers websites [101-105], and are the maximum over all currently available protocols with the system in question. The same holds for throughput, and times are the shortest for the given throughput. Base error rate, from the same sources, should be taken as a rough indicator only as the details of errors vary. It is an average for the read, or for a fixed number of bases from the start of the read (which is stated in this case).